Should I get a comprehensive genomic panel for Triple-Negative Breast Cancer

Genomic Testing for Triple-Negative Breast Cancer: What You Should Know

This is an excellent question, and the answer depends on several factors specific to your situation. Let me break down what the evidence shows and help you think through this decision with your care team.

Why Genomic Testing Matters for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is particularly aggressive because it lacks three common treatment targets: estrogen receptors (ER), progesterone receptors (PR), and HER2. This means traditional hormone therapies don't work, making comprehensive genomic analysis especially valuable for finding alternative treatment pathways.

According to the CancerPatientLab webinar featuring Dr. [removed] Lopez-Correa (an MD/PhD who navigated her own breast cancer), comprehensive genomic testing can reveal actionable mutations that standard pathology reports might miss. For example, she discovered an AKT1 mutation through whole genome sequencing that wasn't captured by standard tests—and this finding was critical for prescribing CDK4/6 inhibitors, which target aggressive tumor behavior.

What Tests Should You Consider?

For Triple-Negative Breast Cancer specifically, germline genetic testing (BRCA1/BRCA2) is particularly important. According to the educational guidelines:

• Triple-negative patients under 60 should be offered germline testing to identify inherited mutations that may impact treatment and family risk
• This is especially relevant because TNBC has higher rates of BRCA mutations compared to other breast cancer types

Beyond germline testing, consider:

1. Whole genome or whole exome sequencing of your tumor tissue - This provides comprehensive analysis of mutations specific to YOUR cancer, not just inherited ones
2. Ki-67 testing - Measures how fast your tumor cells are dividing (important for TNBC, which tends to be fast-growing)
3. Circulating tumor DNA (ctDNA) tests like Signatera - For monitoring minimal residual disease (MRD) after treatment

The Important Caveat: "Actionable" vs. "Informational"

Here's a critical distinction Dr. [removed]-Correa emphasized: not all genetic findings are immediately actionable. Some tests reveal mutations for which no standard treatment currently exists. This raises important questions:

• Will the results change your treatment plan?
• Are the mutations "druggable" (meaning drugs exist to target them)?
• Will the information help with surveillance and monitoring?

Your oncologist should be able to explain which findings would actually influence your care decisions.

Key Questions to Ask Your Oncologist

1. "Do you recommend comprehensive genomic testing for my triple-negative breast cancer? Why or why not?"

2. "If we do genomic testing, which specific mutations would be actionable—meaning they would change my treatment recommendations?"

3. "Should I get germline (inherited) genetic testing? Do I meet the criteria for BRCA testing?"

4. "What about circulating tumor DNA testing to monitor for minimal residual disease after treatment?"

5. "If testing reveals mutations without current standard treatments, how would that information be used to guide my care?"

6. "Are there clinical trials I might be eligible for based on my tumor's molecular profile?"

7. "What are the costs, and what does my insurance cover?"

The Access and Equity Reality

Dr. [removed]-Correa also highlighted an important challenge: not all oncologists routinely offer or discuss genomic testing, even though the technology exists. Some barriers include:

• Cost (comprehensive testing can range from $1,000-$6,000+)
• Limited insurance coverage
• Lack of awareness among some healthcare providers
• Complexity of interpreting results

You may need to advocate for yourself and ask directly about these options rather than waiting for your doctor to suggest them.

Bottom Line

For triple-negative breast cancer, comprehensive genomic testing is increasingly valuable because:

• Standard hormone therapies don't work, so finding alternative pathways is critical
• TNBC has higher rates of actionable mutations
• Results can guide treatment selection and identify clinical trial opportunities
• Germline testing is specifically recommended for TNBC patients under 60

However, the decision should be made collaboratively with your oncologist based on:

• Your specific stage and treatment plan
• Whether results would actually change your care
• Your personal preferences about having genetic information
• Insurance coverage and cost considerations

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Sources Referenced:

• CancerPatientLab Webinar: "An MD PhD Navigates Breast Cancer" (Catalina Lopez-Correa, MD, PhD) - discusses comprehensive genomic testing, actionable mutations, and patient advocacy in genetic testing decisions
• Educational guidelines on germline testing recommendations for triple-negative breast cancer patients under 60